Increased Fluorodeoxyglucose Uptake Following Endovascular Abdominal Aortic Aneurysm Repair: A Predictor of Endoleak? by Paraskevas, Kosmas I et al.
  The Open Cardiovascular Medicine Journal, 2010, 4, 117-119 117 
 
  1874-1924/10  2010 Bentham Open 
Open Access 
Increased Fluorodeoxyglucose Uptake Following Endovascular Abdominal 
Aortic Aneurysm Repair: A Predictor of Endoleak?  
Kosmas I. Paraskevas
1,*, Alexandros A. Tzovaras
2, Vassilios Stathopoulos
3, Fotini Gentimi
4 and 
Dimitri P. Mikhailidis
5 
1Department of Vascular Surgery, Red Cross Hospital, Athens, Greece 
21
st Department of Oncology, Aghios Savvas Hospital, Athens, Greece 
32
nd Department of Surgery, Rhodes General Hospital, Rhodes, Greece 
42
nd Department of Pediatric Surgery, Aghia Sophia Children’s Hospital, Athens, Greece 
5Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University 
College London Medical School, University College London (UCL), London, UK 
Abstract: The main criterion for abdominal aortic aneurysm (AAA) repair is an AAA diameter 5.5 cm. However, some 
AAAs rupture when they are smaller. Size alone may therefore not be a sufficient criterion to determine rupture risk. 
Fluorodeoxyglucose (FDG) uptake is increased in the presence of inflammation and it was suggested that this may be a 
better predictor of rupture risk than AAA size. Furthermore, increased FDG uptake following endovascular AAA repair 
may be an indirect predictor of continuous AAA sac enlargement due to the presence of an endoleak (even if this is not 
detected by imaging modalities) and/or increased AAA rupture risk. The role of FDG uptake needs to be explored further 
in the management of AAAs.  
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INTRODUCTION 
  According to current guidelines [1] the main criterion   
for abdominal aortic aneurysm (AAA) repair is a diameter 
5.5 cm. However, smaller AAAs can rupture and AAAs are 
discovered after exceeding this diameter without rupturing 
[2, 3].
  
  Fluorodeoxyglucose (FDG) uptake, measured by positron 
emission tomography (PET), is increased in the presence of 
inflammation [4]. In turn, AAAs are characterized by activa-
tion of inflammatory/immune cells causing degradation of 
elastin and collagen, destruction of medial elastic tissue, me-
dial neovascularization and a decrease in vascular smooth 
muscle cells [5].
 It follows that an association between FDG 
uptake by the AAA wall and the processes leading to rupture 
has been reported [3, 6, 7].  
  Although FDG correlates with inflammation of the AAA 
wall and rupture risk [3, 6, 7], it does not correlate with 
maximal AAA diameter [8].
  Nevertheless, it was recently 
proposed that FDG may be a better predictor of AAA insta-
bility and rupture than AAA size [9]. Such an association 
holds implications for the management of AAAs [9].
 FDG 
uptake may also predict endoleaks following endovascular  
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AAA repair (EVAR) even if this is not detected by imaging 
modalities. This article considers this hypothesis. 
INCREASED FDG UPTAKE AFTER EVAR: AN   
INDIRECT SIGN OF AN ENDOLEAK? 
  The most common complication of EVAR is an endoleak 
which is the persistence of perigraft blood flow inside the 
AAA sac [10-13]. Endoleaks are associated with adverse 
outcomes, including AAA sac growth, the need for conver-
sion to open repair, high reintervention rates and rupture [10-
13]. Therefore, following EVAR long-term (possibly life-
long) imaging surveillance is recommended [10-13]. 
  Several imaging techniques for the surveillance of pa-
tients following EVAR have been described including plain 
radiography, ultrasound, computed tomography (CT)/CT 
angiography and magnetic resonance (MR) imaging/MR 
angiography [13, 14]. Each technique has its advantages and 
disadvantages [13, 14].
 Despite the availability of advanced 
imaging modalities some endoleaks may still be missed. 
Poor compliance with the follow-up schedule may be a rea-
son but in some cases, the endoleak is missed due to techni-
cal deficiencies/shortcomings [12, 15-18].  
  A recent report systematically reviewing the pathogene-
sis, etiology and timing of AAA rupture following EVAR 
identified a total of 270 patients with AAA rupture after 
EVAR [12]. The cause of AAA rupture was known for 235 
patients. Endoleaks were the main cause of rupture in 160 of 118    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Paraskevas et al. 
the 235 patients (type IA: 57 patients; type IB: 31 patients; 
type II: 23 patients; type III: 26 patients; type IV: 0 patients; 
endotension: 9 patients). The endoleak type was not speci-
fied in 14 cases with rupture due to endoleak [12].  
  The presence of an endoleak at the last follow-up before 
rupture was described for only 56 of the 160 patients in 
whom the main cause of rupture was an endoleak [12]. A 
description of the course of AAA sac diameter during fol-
low-up was presented in 101 patients. Enlargement of the 
AAA sac during follow-up occurred in 36 of these patients, 
no change was seen in 39 and shrinkage was reported in 26 
patients. In 35 patients no abnormalities were found during 
follow-up (absence of endoleak, wire fractures, migration, 
graft angulation, insecure fixation, signs of inflammation and 
sac enlargement). In another 6 patients only a small type II 
endoleak was found during follow-up while the AAA sac 
was stable or shrunken. So, in 41 patients no abnormalities 
were found during follow-up that required re-intervention 
[12].  
  Another study evaluated the incidence and impact of pre-
viously unrecognized type II endoleaks using a modified 
intraoperative angiographic protocol (namely the use of digi-
tal subtraction fluoroscopy continuously for 60 sec after in-
jections of 20 ml iodinated contrast both in the pararenal 
aorta and within the endovascular graft) [16]. A total of 391 
patients undergoing EVAR were evaluated (standard com-
pletion angiograms: 264 patients; modified angiographic 
protocol: 127 patients). Type II endoleaks were detected 
intraoperatively in more patients in whom the modified 
compared with the standard angiographic protocol was used 
(53 of 127 vs 12 of 264, or 41% vs 6%, respectively; 
p<0.001) [16]. A third study aimed to analyze the clinical 
implications of endoleaks documented by CT angiography 
which were missed by color duplex ultrasound in 232 pa-
tients undergoing EVAR during a 5-year period [17]. All 
patients were followed by both CT angiography and color 
duplex ultrasound at 1 month following the procedure and 
every 6 months thereafter. A total of 39 endoleaks were de-
tected using CT angiography compared with only 28 using 
ultrasonography. Overall, color duplex ultrasonography 
failed to identify an endoleak in >25% of the cases (11 of 39 
endoleaks [28%]; 2 late type I, 6 early type II, 2 late type II 
and 1 early type IV) [17]. Finally, in a single-center report of 
445 AAA patients treated endovascularly, late AAA rupture 
occurred in 3 cases [18]. In all cases, the reason for rupture 
was type I endoleak that was not diagnosed during post-
EVAR surveillance scans [18].
  
COMMENT 
  Despite a wide variety of imaging modalities, some 
endoleaks are missed [12, 15-18]. Ultrasonography is a cost-
effective and reproducible method that identifies an endoleak 
in the majority of the cases; nevertheless, it may miss as 
many as 28% of endoleaks [17]. Due to its cost-
effectiveness, ultrasonography should remain the primary 
diagnostic tool for detecting endoleaks following EVAR. 
When a follow-up ultrasound examination is negative, how-
ever, FDG uptake could represent an investigation which 
could alert the physician about the presence of an endoleak 
following EVAR. However, since most ultrasound examina-
tions will be negative, the cost of an additional investigation 
by FDG uptake is prohibitive unless there is a high index of 
clinical suspicion of an endoleak. Moreover, the FDG uptake 
will not accurately reveal the location of the endoleak and 
AAA infection could lead to increased FDG uptake (due to 
local inflammation) and result in misinterpretation [19]. As 
FDG represents an inflammatory state [3-7], it would be in-
teresting to explore the role of drugs possessing anti-
inflammatory action.  Through inhibition/decrease of AAA 
expansion rates, statins may play a role in the management 
of AAAs [20]. Oxidative stress may play a role in the patho-
genesis of AAAs; thus statins may exert their growth inhibi-
tory effect by interfering with this pathway [21]. Irrespective 
of an effect on AAA growth, all AAA patients undergoing 
surgery [22] or a percutaneous intervention [23] should re-
ceive statin therapy to improve perioperative morbidity and 
mortality rates. Future studies should investigate the effect of 
statin therapy on post-EVAR patients exhibiting increased 
FDG uptake. 
  Apart from research applications, FDG uptake may prove 
useful in predicting the risk of rupture in AAA with a diame-
ter below the threshold for intervention as assessed by ultra-
sound. This is of interest since there is a current debate as to 
whether there are grounds for intervening with EVAR in 
AAAs below the threshold diameter. Based on the lower 
perioperative mortality rates associated with EVAR com-
pared with open surgical procedures [24], it was proposed 
that the current size threshold for elective AAA repair may 
need to be lowered in the endovascular era [25, 26]. Two on-
going multicentre randomized controlled trials, Comparison 
of surveillance versus Aortic Endografting for Small Aneu-
rysm Repair (CAESAR) [25] in Europe and Positive Impact 
of endoVascular Options for Treating Aneurysms earLy 
[PIVOTAL] [26] in the United States are currently compar-
ing EVAR vs surveillance for AAAs <5 cm in size. This 
argument would be supported even further if a reliable pre-
dictor (i.e. FDG uptake) of expansion and possible eventual 
rupture risk was available. This option requires further con-
sideration.  
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